Beinaglutide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Beinaglutide is the only GLP-1 drug on the market that is the plain, unchanged human hormone. That is why it has to be injected three times a day. It is approved in China. In a large final-stage study of 427 people, weight fell 6.0 percent on it, against 2.4 percent on a dummy shot, over 16 weeks.
Evidence grade for Beinaglutide: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 2 completed trials, 443 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 443
- Human studies
- 2
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 443 people given it
No first-hand reports gathered yet. That is a gap in what we have collected, not a finding that nothing has been reported.
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Beinaglutide is the plain human hormone GLP-1, made in a lab. Your gut makes the same hormone after a meal. Your body clears it in minutes, so the drug is a shot three times a day before meals. It is approved in China for diabetes and for weight loss.
What people take it for
- Weight loss.
- Lower blood sugar in type 2 diabetes.
- Fatty liver and PCOS, in smaller studies.
What studies in people showed
The biggest study had 427 Chinese adults without diabetes. Over 16 weeks, weight fell 6.0 percent on the drug and 2.4 percent on a dummy shot. 21.3 percent of people on the drug lost at least a tenth of their weight. Nausea hit 49.3 percent of people on the drug, against 7.1 percent on the dummy shot. A look back at the records of 314 patients showed 10.05 kg lost in three months. That is much more than the careful study found, so do not trust it. In mice, it changed how fat tissue stores fat.
What people report
Reports, not study results
The good
- People lost some weight. 58.2 percent on the drug lost at least 5 percent of their weight.
- It is the body's own hormone, so the body is less likely to make antibodies against it.
The bad
- Nausea is common. About half of people on it felt sick in the big study.
- 5.9 percent quit because of side effects, against 0.7 percent on the dummy shot.
- Three shots a day is hard to keep up.
- Weight started coming back after people stopped.
Where these come from: The study results on this page. We have not collected user reports on this one yet.
My bottom line
It works, but only a little, and three shots a day plus nausea is a tough deal. Its real use is showing how much of the newer drugs' effect comes from lasting longer. I would not chase it.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Beinaglutide has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weight741 people · 2 studies
- Blood sugar and insulin314 people · 1 study
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none. The record on this one is set out below.
- Losing fat specifically1 animal or lab study
33 of the 36 indexed goals have no study of any kind behind Beinaglutide
No study in people, animals or cells on this page reports a result for these. That does not prove Beinaglutide does nothing for them. It does mean anything you have heard about Beinaglutide and one of these did not come from a study cited here.
Show full evidence
What is Beinaglutide?
Beinaglutide is the only GLP-1 drug on the market that is the plain, unchanged human hormone. That is why it has to be injected three times a day. It is approved in China. In a large final-stage study of 427 people, weight fell 6.0 percent on it, against 2.4 percent on a dummy shot, over 16 weeks.
Every other drug in this family is the human hormone rebuilt to last in the blood. One swaps a building block so a body enzyme cannot break it down. One adds a fatty chain that sticks to a blood protein. One joins on a piece of antibody to slow clearing. Beinaglutide has none of that. It is lab-made human GLP-1, the exact hormone your gut releases after a meal.
That choice shapes everything about the drug. Your body clears natural GLP-1 in minutes. So beinaglutide is injected three times a day, before meals. In the first safety study, blood levels peaked within about fifteen minutes and then fell.
It has been sold in China for type 2 diabetes for years. China's regulator approved it for weight loss in July 2023. That made it one of the first GLP-1 drugs approved for weight loss anywhere, and the second in China.
The weight result is real but modest. In a 427-person study where nobody knew who got the drug, 16 weeks of shots three times a day took off 6.0 percent of body weight. The dummy-shot group lost 2.4 percent. That is a gap of 3.6 points. 58.2 percent of people on the drug lost at least 5 percent. Semaglutide 2.4 mg and tirzepatide produce weight loss in the mid-teens in longer studies. That is a different size of effect.
The most eye-catching number for beinaglutide does not come from a careful study. Researchers looked back at the records of 314 Chinese patients. They reported 10.05 kg of weight loss and a 2.87-point drop in average blood sugar over three months. That is far bigger than the careful studies show. Looking back at records with no comparison group tends to blow up results like this.
How does Beinaglutide work?
It is lab-made human GLP-1, identical to the hormone your gut makes. It works exactly like the natural hormone. It helps the pancreas release insulin when blood sugar is high. It holds back glucagon, a hormone that raises blood sugar. It slows the stomach and turns down hunger through nerves and the brain. Nothing has been changed to protect it from the enzyme that breaks it down, and nothing makes it stick to blood proteins. So the body clears it as fast as its own GLP-1. That is why it is taken before each main meal, not once a week. In obese mice on a fatty diet, it changed the fats stored in fat tissue and the genes that handle fat, and fat tissue responded better to insulin.
What have studies in people found about Beinaglutide?
A 427-person final-stage study for weight loss where nobody knew who got the drug. Several diabetes studies, including a comparison with a premixed insulin (insulin aspart 30) and use with insulin glargine. An early study of how the body handles it, and a large look-back at patient records. Several reviews have pooled the studies.
- Final-stage study, 16 weeks, 427 adults without diabetes: weight fell 6.0 percent, against 2.4 percent on a dummy shot. Nausea hit 49.3 percent, against 7.1 percent.
- Diabetes studies exist with the drug alone, with metformin, with insulin glargine, and against a premixed insulin (insulin aspart 30). The last one also checked for antibodies against the drug.
- A look-back at the records of 314 patients reported 10.05 kg of weight loss at three months. That is about three times what the careful studies found.
- Smaller studies have looked at fatty liver in people with type 2 diabetes, and at weight loss in obese women with polycystic ovary syndrome (PCOS).
- An early study in 16 people confirmed the drug is cleared very fast. That is what forces shots three times a day.
What this does not tell you: The careful weight study lasted 16 weeks. That is nowhere near the 68-week and 72-week studies behind semaglutide 2.4 mg and tirzepatide, and the weight loss is about a third of theirs. Almost every study was in China, so the people do not match Western body weights and diets. There is no heart attack and stroke study. And three shots a day is the real-life fact that decides whether anyone sticks with it. The studies only tracked that over months.
The state of the research
Beinaglutide is useful on this site for a reason separate from whether anyone should take it. It is the baseline for the whole drug family.
Every change in semaglutide, liraglutide, dulaglutide and the rest exists to solve one problem. Natural GLP-1 disappears within minutes. Beinaglutide shows what the plain hormone does when you give it as a drug. It lowers blood sugar, it causes weight loss, and it was approved for both. It just has to be injected before every main meal. Its weight effect is a fraction of what the long-lasting versions achieve.
That tells you something the marketing does not. The gap between 6 percent and 15 percent weight loss is mostly not about a better signal. It is about how long the signal stays switched on. Lasting longer, not a cleverer signal, is most of what the modern drugs added.
One more thing to flag. The look-back study reporting 10 kg of weight loss in three months gets passed around a lot. It is roughly three times what the careful final-stage study found over a longer time. When you only look at people who chose a drug and stayed on it, you mostly see the people it suited. The number from the careful study is the honest one.
A note on what Chinese approval does and does not tell you. China's drug regulator requires studies in Chinese patients. The key studies behind these approvals are real, carefully run studies with a dummy-shot group. They are published in mainstream medical journals, including Diabetologia, Nature Communications, Diabetes Obesity and Metabolism and the Lancet regional journal. What is usually missing, compared with the Western drugs, is a big study of heart attacks and strokes. Semaglutide and liraglutide have heart data in tens of thousands of patients followed for years. None of the drugs on this page does. So the fair statement is this. These drugs lower blood sugar and body weight in Chinese adults over months. They have not been shown to prevent heart attacks. That gap is real. It is a separate question from whether a Western reader has heard of the drug.
The evidence, in charts
Fig. 1a · how many people
757people, across 3 studies in people cited here
| Study | People | Share |
|---|---|---|
| Diabetes, Obesity and Metabolism 2024 | 427 | 56% |
| Obesity Science and Practice 2019 | 314 | 41% |
| Frontiers in Pharmacology 2024 | 16 | 2% |
One study holds 56% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 4 sources here are studies in people. The rest is not.
- Study in people · done in people375%
- Animal study · done in animals125%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 3 different years, 2019 to 2024, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- About 3.3 kDa, the mass of human GLP-1 (7-36) amide.
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
Half-life as stated on file: Very short, because it is the unmodified human hormone. It is injected three times daily before meals, and in the phase one study plasma concentrations peaked within roughly fifteen minutes and then declined.
No amino acid sequence is on file for Beinaglutide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2024Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study
Three shots a day for 16 weeks took off a modest amount of weight, and half the people felt sick. 427 Chinese adults without diabetes were split by chance to 0.2 mg under the skin three times daily or a dummy, and nobody knew which. Weight fell 6.0 percent against 2.4 percent on the dummy. Nausea hit 49.3 percent against 7.1 percent, and 5.9 percent quit over side effects against 0.7 percent. Weight started coming back once people stopped.
Multicentre double-blind placebo-controlled phase 3 in 427 non-diabetic Chinese adults, randomised 2:1 to 0.2 mg subcutaneously three times daily or placebo for 16 weeks. Mean body weight change was minus 6.0 percent against minus 2.4 percent, a difference of 3.6 percentage points. 58.2 percent versus 25.4 percent lost at least 5 percent and 21.3 percent versus 5.1 percent lost at least 10 percent. Nausea occurred in 49.3 percent against 7.1 percent, and 5.9 percent discontinued for adverse events against 0.7 percent. Weight regain 12 weeks after stopping was reported at 0.78 percent.
- Study in people2024Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight/obesity: results from a phase I clinical trial
Sixteen people, and the study measured how the drug moves through blood. The volunteers were overweight or obese Chinese adults at one centre, taking 0.1, 0.14 or 0.2 mg three times a day, all of them knowing what they took. Levels peaked around 15 minutes after each shot. Bigger doses gave proportionally more drug in the blood, and nothing built up with repeated dosing. Men and women handled it differently. This tells you how the drug behaves, not whether it does anything for anyone.
Open-label single-centre multiple ascending dose phase 1 in 16 overweight or obese Chinese volunteers at 0.1, 0.14 and 0.2 mg three times daily. Concentrations peaked around 15 minutes with a median time to maximum concentration of 10 to 15 minutes, exposure rose in proportion to dose, and no accumulation occurred with repeated dosing. A sex difference in pharmacokinetics was observed. Sixteen people; this establishes how the drug behaves in blood, not whether it works.
- Study in people2019Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study
Nobody was given anything here. Researchers looked back at the records of 314 Chinese patients with type 2 diabetes. After three months, the records showed weight down 10.05 kg and average blood sugar down 2.87 points. Those numbers are far bigger than the careful study with a dummy-shot group found. Looking back only at people who stayed on a drug picks out the ones it suited. These figures should never be quoted as what the drug does.
Retrospective observational data on 314 Chinese patients with type 2 diabetes treated between 2017 and 2018. After three months, weight fell 10.05 kg and glycated haemoglobin 2.87 percentage points, with 84.96 percent losing at least 5 percent of body weight. These figures are far larger than the randomised phase 3 produced, which is what uncontrolled retrospective selection does to effect estimates, and they should not be quoted as the drug's effect size.
- Animal study2021Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice
In mice made obese on a fatty diet. Treated mice had lower weight, less fat and lower blood fats. Their fat tissue responded better to insulin. The kinds of fat stored in that tissue changed, and so did the genes that handle fat. None of this has been measured in a human study of this drug.
Diet-induced obese mice. Treated animals showed lower body weight, fat mass and plasma lipids, improved insulin sensitivity in white adipose tissue, and changes in the content and composition of glycerolipids, glycerophospholipids and sphingolipids alongside altered expression of lipid metabolism genes. A mouse mechanism study; none of these lipidomic endpoints has been measured in a human trial of this drug.
Where to buy Beinaglutide
1 seller lists Beinaglutide in our latest read. They are ranked by trust score, then by archive rating, then by certificate tier, then by the lowest price per milligram. Archive evidence is counted before source-backed. Each path is out of 4, and the two are not added. A higher price does not raise the score. The letter is the certificate chip. 0 of them have a published certificate that names Beinaglutide.
Some seller links may pay this site when you buy through them. A payment never changes a seller's tier or rank, and no seller has a say in any page.
| Seller | Trust score | Vial sizes | From, per mg | Certificate for Beinaglutide | Seller link |
|---|---|---|---|---|---|
| Arizona Mall | 36 WeakSource-backed 1 of 4. Archive evidence 1 of 4.C | 4.2 mg | $0.238 | None found for Beinaglutide | View |
- LC Lab-confirmed: the issuing laboratory echoed this certificate back
- A Current certificate, independent laboratory named, laboratory not yet checked
- B Certificate published, but no laboratory link, older than a year, or the laboratory did not recognise the published lookup
- C No certificate could be read
Every listing and vial size for Beinaglutide · How the trust score is counted
Sellers named on the price pages are ranked by certificate tier, then price, and any affiliate income is disclosed there. Naming a seller is not a recommendation to buy or use anything.
Common questions
Has Beinaglutide been tested in people?
Yes. 443 people given it across 2 completed trials cited here, 0 of which found nothing. Beinaglutide is the only GLP-1 drug on the market that is the plain, unchanged human hormone. That is why it has to be injected three times a day. It is approved in China. In a large final-stage study of 427 people, weight fell 6.0 percent on it, against 2.4 percent on a dummy shot, over 16 weeks.
What is the Beinaglutide dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 2 completed trials, 443 people given it
Is Beinaglutide FDA-approved?
Not approved in the United States. Sold in China for type 2 diabetes. China's drug regulator, the National Medical Products Administration, also approved it for weight loss in July 2023.
Why is beinaglutide injected three times a day?
Because it is plain human GLP-1. Your body breaks down and clears natural GLP-1 within minutes. This drug has nothing added to slow that down: no fatty chain, no swapped building block, no attached protein. Blood levels peak about fifteen minutes after a shot and then fall. So it is taken before each main meal.
How much weight do people lose on it?
In the 427-person final-stage study, 6.0 percent over 16 weeks, against 2.4 percent on a dummy shot. 58 percent lost at least 5 percent of their weight, and 21 percent lost at least 10 percent. A look-back study that is quoted a lot reports 10 kg in three months. That number comes from patient records with no comparison group. It should not be treated as what the drug does.
Is it as good as semaglutide?
For weight loss, the numbers are far apart. Studies of semaglutide 2.4 mg report weight loss in the mid-teens over 68 weeks. This drug reports 6 percent over 16 weeks. No study has compared them directly, and the different study lengths make any side-by-side guess rough.
Is it approved anywhere?
In China. It has been sold there for type 2 diabetes. China's drug regulator approved it for weight loss in July 2023. It is not approved in the United States, United Kingdom, Australia or Canada.
Does being identical to the human hormone make it safer?
It removes one worry. The body is less likely to make antibodies against its own hormone. That is a real issue for drugs based on the lizard hormone exenatide, or built from joined proteins. It does not remove the usual side effects of this drug family. In the final-stage study, nausea hit 49.3 percent of people on the drug, against 7.1 percent on a dummy shot, and 5.9 percent stopped because of side effects.